Academic literature on the topic 'Voie MAPK/ERK'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Voie MAPK/ERK.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Voie MAPK/ERK"
Chemouny, J. M., H. Tamouza, L. Berthelot, M. Flamant, L. Mesnard, F. Walker, E. Tissandié, et al. "L’activation de la voie de signalisation MAPK/ERK dans les cellules mésangiales est associée aux lésions glomérulaires dans la néphropathie à IgA et permet de prédire la réponse aux antiproteinuriques." Néphrologie & Thérapeutique 8, no. 5 (September 2012): 288–89. http://dx.doi.org/10.1016/j.nephro.2012.07.345.
Full textGerby, Bastien, Florence Armstrong, Philippe Brunet de la Grange, Julien Calvo, Paula Ballerini, and Françoise Pflumio. "Mise en évidence des cellules souches leucémiques dans les LAL-T humaines et étude de l’implication des voies NOTCH, TAL1 et ERK/MAPK dans la leucémogenèse T humaine." Annales de Pathologie 28, no. 1 (November 2008): S28—S29. http://dx.doi.org/10.1016/j.annpat.2008.09.004.
Full textKhan, M. A. Muqtedar. "Islamic Democracy and Moderate Muslims." American Journal of Islamic Social Sciences 22, no. 3 (July 1, 2005): 39–50. http://dx.doi.org/10.35632/ajiss.v22i3.468.
Full textKhan, M. A. Muqtedar. "Islamic Democracy and Moderate Muslims." American Journal of Islam and Society 22, no. 3 (July 1, 2005): 39–50. http://dx.doi.org/10.35632/ajis.v22i3.468.
Full textDissertations / Theses on the topic "Voie MAPK/ERK"
Valjent, Emmanuel. "La voie mapk/erk : un substrat neurobiologique de la dependance aux substances toxicomanogenes." Paris 6, 2001. http://www.theses.fr/2001PA066378.
Full textHaupaix, Nicolas. "Régulation de la voie MEK/ERK par la signalisation éphrine lors du développement neural chez l'ascidie Ciona intestinalis." Phd thesis, Université Nice Sophia Antipolis, 2014. http://tel.archives-ouvertes.fr/tel-01059798.
Full textCagnol, Sébastien. "Contrôle de la mort cellulaire par la voie des MAPK 1/3 (ERK 2/1)." Nice, 2005. http://www.theses.fr/2005NICE4033.
Full textProgrammed cell death or"apoptosis"is an evolutionary conserved feature of multicellular organisms necessary for normal development and tissue homeostasis. In living cells, the activity of the proteases that execute the apoptotic cell death program, the caspases, is controlled by survival signals emanating from the cellular environment. The regulatory components of the caspase cascade, caspase 9 and caspase 8, are activated respectively by the apoptosome and by death receptors. Survival signals elicited by extracellular matrix or growth factors activate signaling pathways that control the cell death machinery. The MAPK1/3 signaling pathway is a kinase cascade comprising Raf, MEK1/2 and MAPK1/3 (ERK1/2 or p42/p44 MapKinases) regulated by the proto-oncogene Ras. The MAPK1/3 pathway is implicated in cell proliferation and differentiation and plays an essential role in cell survival. This thesis objective was to characterize the molecular mechanisms involved in the control of cell death by MAPK1/3 pathway. This study relies on the use of an inducible form of Raf-1 kinase (DRaf-1:ER) those strong and persistent activation leads to a pathological induction of MAPK1/3 activity. We have been able to show that, depending on the cell type, DRaf-1:ER activation favors cell survival or induces cell death. In the lung fibroblastic cell line CCL39, DRaf-1:ER activation prevents cell death induced by serum withdrawal from the tissue culture medium. Under this experimental setting, we could show that DRaf-1:ER stimulation inhibits caspase 9 activation but did not prevent cytochrome c release, APAF1 oligomerization and caspase 9 recruitment in the apoptosome. This novel mechanism of cell death inhibition at a post-mitochondrial level requires ongoing protein synthesis and continuous MEK kinase activity. In HEK293, an embryonic kidney cell line that bares properties of neuronal lineage cells, sustained activation of the MAPK1/3 pathway in response to DRaf-1:ER induces massive cell death. Cell death is characterized by caspases activation and DNA fragmentation. It is a slow process, detectable more than 24 hours after DRaf-1:ER stimulation and maximal at 48 hours. Cell death induction needs protein synthesis only during the early stage of activation but requires a continuous activity of the MEK/MAPK module. Cell death results from caspase 8 activation and does not require the mitochondrial pathway of apoptosis. It is characterized by the formation of vacuoles in the cytoplasm that evoke paraptosis, a particular form of apoptosis. Functional inactivation of the death receptor Fas or its adaptator FADD indicates that the activation process of caspase 8 is independent of the death receptor pathway. Altogether, these results extend our understanding on the role of the Raf/MAPk pathway in the control of cell death. We have shown that in different cellular context, this signaling pathway can either promote cell survival or induce cell death. In both cases, cell death control requires protein synthesis and post-traductionnal modifications. Molecular mechanisms that respond to prolonged MAPK1/3 activation could be involved in tumor resistance to proapoptotic treatments as well as in the development of neurodegenerative diseases
Aoidi, Rifdat. "Étude du rôle de la voie ERK/MAPK dans le développement embryonnaire chez la souris." Doctoral thesis, Université Laval, 2017. http://hdl.handle.net/20.500.11794/27476.
Full textLes mammifères possèdent deux MAP kinases kinases (MEK1 et MEK2), impliquées dans l’activation de la voie ERK/MAPK essentielle pour la différenciation, la prolifération et la survie cellulaire. Le premier objectif de cette thèse était de déterminer si les fonctions des kinases MEK1 et MEK2 sont redondantes durant le développement embryonnaire. Les souris Mek1-/- meurent à mi-gestation d’une malformation du placenta. Les souris Mek2-/- ne présentent aucun phénotype majeur, suggérant que ces deux protéines ont des rôles différents. Cependant, la plupart des mutants Mek1+/-Mek2+/- meurent pendant la gestation d’un sous-développement du placenta, indiquant que Mek1 et Mek2 ont chacun un rôle dans le développement des tissus extraembryonnaires. À ce jour aucune évidence claire ne permet de statuer sur la redondance fonctionnelle de MEK1 et MEK2. Afin de vérifier la spécificité fonctionnelle de Mek1 et Mek2, nous avons généré au laboratoire un allèle « knockin », exprimant l’ADNc de Mek2 sous contrôle du locus Mek1 (Mek12). L’analyse de ces souris a révélé la redondance fonctionnelle entre MEK1 et MEK2. L’analyse de combinaisons alléliques de Mek a démontré qu’une expression minimale de protéines MEK est cruciale pour le développement embryonnaire et la survie. Le second objectif de cette thèse était de caractériser les mutants Mp1. Les protéines d’échafaudage permettent de moduler l’activité de la voie ERK/MAPK et facilitent la transmission rapide du signal. Parmi les protéines d’échafaudage connues, seule MP1 (Mek Partner 1) a été identifiée comme étant un partenaire spécifique de MEK1 et ERK1. Cette spécificité suggère que MP1 pourrait contribuer à la différence d’activation de MEK1 et MEK2 en spécifiant le signal qui passe par Mek1. Afin d’étudier le rôle de Mp1 au cours du développement chez la souris, nous avons généré des souris Mp1-/-. L’analyse de ces mutants indique que le gène Mp1 est essentiel pour la survie et que sa fonction est nécessaire suite à la post-implantation. La dérégulation de la voie ERK/MAPK dans le développement chez l’homme a aussi des conséquences phénotypiques. Au cours des dernières années, une classe de syndromes a été caractérisée : Les « Rasophaties ». Ces syndromes partagent des caractéristiques communes qui sont, une mutation dans des gènes de la voie ERK/MAPK, une dysmorphologie cranio-faciale, des malformations cardiaques et cutanées ainsi qu’un retard mental. Parmi les mutations de la voie ERK/MAPK qui ont été identifiées, une mutation ponctuelle dans le gène Mek1 (Mek1Y130C) cause le syndrome Cardio-Facio-Cutané (CFC). Le dernier objectif de cette thèse était de générer un modèle animal pour le CFC portant la mutation Mek1Y130C. Les souris portant l’allèle Mek1Y130C présentent les phénotypes associés au CFC (i.e sténose pulmonaire, dysmorphologie cranio-faciale et défauts neurologiques).
Mammals possess two MAP kinase kinase (MEK1 and MEK2), involved in ERK/MAPK pathway. This pathway is essential for proliferation, differentiation and cell survival. The first objective of my thesis was to determinate if MEK1 and MEK2 kinases are redundant during embryonic development. Mek1-/- mice die at embryonic day E10.5 due to placental defects, whereas Mek2-/- mice survive with a normal lifespan suggesting that MEK1 possesses functions not shared by MEK2. However, most Mek1+/-Mek2+/- embryos also die from placental defects, indicating that both Mek genes contribute to placental development. To date, no clear evidence on MEK1 and MEK2 redundancy has been provided. To assess the functional specificity of the Mek1 and Mek2 genes, we produced a Mek1-knockin allele in which the Mek2 coding sequences were placed under the control of Mek1 regulatory sequences. Analyzing these mice allowed us to demonstrate that MEK1 and MEK2 can substitute for each other and that a minimal amount of MEK is critical for placenta development and embryo survival. The second objective of my thesis was to characterize Mp1 mutants. Scaffold proteins modulate MAPK pathway by providing spatial and temporal specificity. Among known ERK/MAPK scaffold proteins, only MP1 (Mek Partner 1) is specific to MEK1 and ERK1, raising the question of the specificity of MP1 in the regulation of ERK/MAPK pathway via MEK1. In order to investigate Mp1 function in vivo, we generated Mp1 knock-out mice. Analyzing these mice enable us to suggest that Mp1 is required for embryonic development and is essential during post-implantation. Deregulation of Ras/MAPK pathway also causes developmental phenotypes in human. During the last decade, a new class of syndromes, which share common phenotypes such as mutations in Ras/MAPK pathway, cranio-facial dysmorphology, cardiac and cutaneous malformations and neurological delay has been described and named Rasophaties. Among the DNA mutations found in rasopathies, the Mek1 mutation, Mek1Y130C, causes cardio-facio-cutaneous syndrome (CFC). The last objective of my thesis was to generate a mouse model of CFC, with the Mek1Y130C mutation. I found that mice carrying the Mek1Y130C mutation partially recapitulate CFC syndrome (i.e pulmonary stenosis, crani-facial dysmophia and neurological defects).
Ghousein, Amani. "MiR-4510 inhibe le développement du carcinome hépatocellulaire en ciblant RAF1 et en inhibant la voie MAPK/ERK." Thesis, Bordeaux, 2018. http://www.theses.fr/2018BORD0020.
Full textAberrant micro(mi)RNA expression signature is a hallmark of many cancers including hepatocellular carcinoma (HCC), a primary malignant liver disease which ranks second in cancer mortality worldwide. Our team previously reported the downregulation of miR-4510 in HCC samples and identified this miRNA as a strong tumor suppressor in liver. Proteomic data analysis collected from Huh7 cells transfected by miR-4510 showed a significant decrease of multiple oncogenes including RAF1 serine/threonine protein kinase. I also found that RAF1 protein level is significantly increased in HCC patients. The role of RAF1 and miR-4510 in HCC being poorly understood, I studied the function of RAF1/miR-4510 pair in tumorigenesis of the liver. My results showed that miR-4510 overexpression significantly decreases both RAF1 protein and mRNA levels and inhibits MAPK/ERK signaling. The dual fluorescence-FunREG assay revealed that miR-4510 directly interacts with RAF1 3’-untranslated region through a unique site. Silencing of RAF1 in two hepatic cell lines by miR-4510 or a specific small interfering RNA suppressed important tumorigenic features (proliferation, migration….) both in vitro and in vivo. Collectively, my data suggest that miR-4510 participates in liver carcinogenesis through RAF1 targeting and MAPK/ERK signaling inactivation. In addition, my study suggests that miR-4510-based therapy may represent a promising strategy to treat patients with advanced or refractory HCC
Simard, François. "Régulation de l'expression génique et de la sécrétion des cytokines chez le neutrophile humain : implication de la voie des MAPK MEK/ERK et son découplage." Mémoire, Université de Sherbrooke, 2012. http://hdl.handle.net/11143/6361.
Full textCagnol, Sébastien. "Contrôle de la mort cellulaire par la voie des MAPK1/3 (ERK2/1)." Phd thesis, Université de Nice Sophia-Antipolis, 2005. http://tel.archives-ouvertes.fr/tel-00104792.
Full textMilanini-Mongiat, Julie. "Etude de la régulation transcriptionnelle du "VEGF" par la voie des MAPK Erk/p42/p44 : activation directe du facteur de transcription Sp1." Nice, 2001. http://www.theses.fr/2001NICE5615.
Full textBuffet, Camille. "Anomalies moléculaires de la voie MAPK et cancer papillaire de la thyroïde : étude de deux phosphatases spécifiques de ERK, DUSP5 et DUSP6." Thesis, Paris 5, 2014. http://www.theses.fr/2014PA05T049/document.
Full textPapillary thyroid cancer (PTC) is the most common endocrine malignancy. Mutually exclusive and activating alterations of the MAPK pathway (Mitogen-Activated Protein Kinases) are identified in 70% of cases. Common mutations found in PTCs are point mutation of the B-RAF (50%) and RAS genes (10%) as well as RET/PTC chromosomal rearrangements (10%). The hot spot B-RAFV600E mutation is the most frequently alteration identified and is connected with agressive clinical characteristics (high stage at diagnosis, high recurrence risk and death). These molecular events lead to constitutive activation of the MAPK pathway, resulting in MEK (Mitogen-activated Extracellular signal-Regulated Kinase) and ERK (Extracellular signal-Regulated Kinase) phosphorylation. ERK is negatively regulated by phosphatases and among them, Dual Specificity Phosphatases (DUSPs), ubiquitary expressed, in particular two ERK-specific phosphatases DUSP5 (nuclear) and DUSP6 (cytosolic). We hypothesized that these phosphatases could have tumor supressor properties (i.e. their loss would be associated with an increase in MAPK pathway activation) or may serve as a surrogate marker of MAPK pathway activation in the context of a negative feedback loop. We analysed regulation and expression of both phosphatases in 3 models: three PCCL3 cell lines (rat thyroid cells) expressing one of the most common oncogene identified in PTCs (RET/PTC3 or H-RASV12 or B-RAFV600E) under the control of a doxycycline-inducible promoter, human PTC-derived cell lines and human PTC. We demonstrated that MAPK pathway activation was correlated with induction of DUSP5 and DUSP6. These phosphatases are involved in a negative feedback loop that contributes to a tight regulation of phospho-ERK levels. DUSP5 and DUSP6 mRNA are overexpressed in human PTCs, especially in B-RAF mutated tumors suggesting a higher MAPK signaling output in these agressive PTCs. Silencing of DUSP5 and/or DUSP6 by small interfering RNA does not affect proliferation of human B-RAFV600E thyroid carcinoma-derived cell lines, suggesting the lack of tumor suppressor gene role. Compensatory changes in expression of DUSPs when a specific one is inactivated may explain this lack of effect. On the opposite, a DUSP6 pharmacological inhibitor induced a concentration dependent decrease in proliferation of human B-RAFV600E cells, suggesting « off-target » effect of this inhibitor. In a second part, we analysed the regulation of DUSP5 expression, which is a target of the MAPK pathway activation. We demonstrated, using pharmacological inhibitors, that DUSP5 is an early response gene, regulated mostly by the MAPK pathway, at the transcriptional level. Two contiguous CArG boxes that bind serum response factor (SRF) were found in a 1Kb promoter region, as well as several E twenty-six transcription factor family binding sites (EBS). These sites potentially bind Elk-1, a transcription factor activated by ERK1/2. Using wild type or mutated DUSP5 promoter reporters, we demonstrated that SRF plays a crucial role in serum induction of DUSP5 promoter activity, the proximal CArG box being important for SRF binding in vitro and in living cells. Moreover Elk-1 was bound in vitro to a promoter region containing the proximal CArG box and a putative EBS. Its specific binding to SRF was necessary to elicit promoter response to dominant positive Elk-VP16 and to enhance the response to serum stimulation. Altogether our results suggest that the MAPK pathway is more active in B-RAFV600E PTC than in PTC with other genetic alteration and could explain their clinical agressivity. DUSP5 and DUSP6, as well as phosphorylated MEK, are markers of activation of the MAPK pathway. Neither phosphatase has tumor suppressor properties in our thyroid cancer cell models. Our results suggest redundancy and functional compensation among DUSPs. (...)
Pétigny-Lechartier, Cécile. "Intérêt de la modulation pharmacologique des voies PI3K / Akt / mTOR et MAPK / ERK pour la sensibilisation des cancers de l'ovaire aux molécules BH3-mimétiques." Thesis, Normandie, 2017. http://www.theses.fr/2017NORMC402/document.
Full textOvarian cancers depend on Bcl-xL and Mcl-1, two anti-apoptotic protein of the Bcl-2 family, for their survival and their inhibition seems to by a relevant strategy. The BH3-mimetic molecule ABT-737 (or its oral form, ABT-263), is a strong Bcl-xL inhibitor, but Mcl-1 inhibition remains problematic. Signaling pathways PI3K/Akt/mTOR and MAPK/ERK regulate expression and activity of Mcl-1 and its BH3-only partners (Bim, Puma, Noxa). We focused on the interest of their inhibition to sensitize ovarian cancer cells to ABT-737. The first study with BEZ235, a PI3K/mTOR dual inhibitor developed by Novartis, inhibits Mcl-1 expression and induces the one of Puma, and sensitizes ovarian cancer cells to ABT-737 provided that Bim expression is induced. The second study evaluated the effects of AZD8055, mTOR active site inhibitor developed by AstraZeneca, and of trametinib, MEK allosteric inhibitor developed by GlaxoSmithKline and currently in clinic, on three ovarian cancer cell lines. Mcl-1 expression inhibition and Puma expression induction by AZD8055 does not sufficiently reduce [Mcl-1/BH3-only proteins] ratio to sensitize cells to ABT-737. On the other hand, strong Bim induction in its active dephosphorylated form by trametinib sufficiently reduce this ratio to sensitize two of the three cell lines tested to ABT-737. Nevertheless, the triple combination AZD8055/trametinib/ABT-737 is the most efficient to induce massive apoptosis in the three cell lines. Besides, interestingly, AZD8055 and trametinib association is cytotoxic without ABT-737 in one of the tested cell lines. These results highlight the efficacy of different multi-targets therapeutic strategies and the need of predictive marker definition of the response to develop personalized treatment and to improve ovarian cancer management
Books on the topic "Voie MAPK/ERK"
Knowles, Kim, and Marion Schmid, eds. Cinematic Intermediality. Edinburgh University Press, 2021. http://dx.doi.org/10.3366/edinburgh/9781474446341.001.0001.
Full textBook chapters on the topic "Voie MAPK/ERK"
Zachar Podolinská, Tatiana. "Traces of the Mary in Post-Communist Europe." In Traces of the Virgin Mary in Post-Communist Europe, 16–55. Institute of Ethnology and Social Anthropology, Slovak Academy of Sciences, VEDA, Publishing House of the Slovak Academy of Sciences, 2020. http://dx.doi.org/10.31577/2019.9788022417822.16-55.
Full text